FAM chemotherapy ± aminoglutethimide in the treatment of pancreatic carcinoma

Allan Lipton, Harold Harvey, R. J. Santen, J. A. Stryker, S. G. Barnes, B. K. Walker, R. H. Dixon, E. M. Givant, M. J. Bartholomew, C. Nadjafi

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Human pancreas contains receptors for estrogens and androgens as well as aromatase activity. FAM chemotherapy was administered to 14 patients with pancreatic cancer (seven at Stage IV). The median survival of these patients was 24.4 ± 4.8 weeks. FAM chemotherapy plus aminoglutethimide/hydrocortisone (AG/HC) (250 mg bid AG + 20 mg bid HC) was administered to 14 patients (seven at stage IV). The median survival of this group was 17.3 ± 2.9 weeks (P = 0.74 vs FAM alone). We conclude that addition of AG/HC does nor add to the survival of patients with carcinoma of the pancreas treated with chemotherapy.

Original languageEnglish (US)
Pages (from-to)12-14
Number of pages3
JournalEuropean Journal of Surgical Oncology
Volume16
Issue number1
StatePublished - Mar 23 1990

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'FAM chemotherapy ± aminoglutethimide in the treatment of pancreatic carcinoma'. Together they form a unique fingerprint.

Cite this